Such an “insulin restriction” state would contribute to the hyperglycemia and hypertriglyceridemia created by RAPA‐treatment, yet maintenance of relatively low PIC (Reifsnyder et al., 2016) and low circulating insulin (Crofts et al., 2015; Johnson, 2021; Klöting & Bluher, 2005; Templeman, Clee, & Johnson, 2017) is often associated with improved metabolic outcomes and reduction of co‐morbidities in chronic disease states. This evidence concerns the gene INS and hypertriglyceridemia.